GGrantIndex
Sort

48,018 grants matching immunotherapy

Immunoengineering Next-Generation Cancer Therapies with Focused Ultrasound

$395,984
Natasha Diba Sheybani · University Of Virginia · DP5 · FY2023 · OD

Bispecific Antibody-Based PET Ligands for Imaging Tauopathies

$395,984
Yu-Shin Ding · New York University School Of Medicine · R21 · FY2020 · AG

Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies

$395,960
Maria G Castro · University Of Michigan At Ann Arbor · R37 · FY2015 · NS

IL-27-mediated immunoregulation in HSV-1-induced stromal keratitis

$395,927
Amol Suryawanshi · Auburn University At Auburn · R01 · FY2023 · EY

Microcarrier / CEF / Media SYSTEM to make Viral Vaccines

$395,902
Solohill Engineering, Inc. · R44 · FY2001 · AI

The Role of HBeAg in HBV Persistence

$395,844
Haitao Guo · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · AI

Untangling the role of dopamine release from Tregs: implications for neurodegeneration at the neuron-immune synapse

$395,837
Ashley E Ross · University Of Cincinnati · R21 · FY2024 · AG

Development of murine glioblastoma model for oncolytic HSV therapy

$395,812
Balveen Kaur · Augusta University · R61 · FY2024 · NS

Project #3:Active Vaccination and Immunotherapy Against Coccidioidomycosis

$395,776
Chiung-Yu Hung · University Of Texas San Antonio · U19 · FY2023 · AI

Targeting tumorigenic pathways in glioblastoma with oncolytic HSV

$395,770
Samuel D Rabkin · Massachusetts General Hospital · R01 · FY2020 · CA

Targeting tumorigenic pathways in glioblastoma with oncolytic HSV

$395,770
Samuel D Rabkin · Massachusetts General Hospital · R01 · FY2021 · CA

Targeting tumorigenic pathways in glioblastoma with oncolytic HSV

$395,770
Samuel D Rabkin · Massachusetts General Hospital · R01 · FY2019 · CA

Discovery & Validation of Biomarkers of Kidney Pathology

$395,740
Brad H Rovin · Ohio State University · U01 · FY2017 · DK

Development of Therapeutic Cancer Vaccine

$395,738
Haifa Shen · Immunoq Therapeutics Inc. · R41 · FY2022 · CA

CD25-mediated feedback control of BCR-signaling and its oncogenic mimics

$395,738
Markus Mãœschen · Beckman Research Institute/City Of Hope · R01 · FY2017 · CA

Ultrasound-controlled remote activation of CAR T cells for localized tumor immunotherapy

$395,733
Yingxiao Wang · University Of California, San Diego · R01 · FY2021 · EB

Immunoengineering Next-Generation Cancer Therapies with Focused Ultrasound

$395,712
Natasha Diba Sheybani · University Of Virginia · DP5 · FY2024 · OD

Telomerase RNA Transfected Dendritic Cell Vaccines

$395,707
Duke University · R01 · FY2003 · CA

Elucidating the role of T-regs in engraftment, GVHD, and DLI immunotherapy

$395,697
Christene A Huang · Massachusetts General Hospital · R01 · FY2013 · AI

Targeting the Vgf signaling system for new chronic pain treatments

$395,600
Lyudmila H Vulchanova · University Of Minnesota · R21 · FY2019 · NS

Molecular Control of Plasmacytoid Dendritic Cell Development and Function

$395,597
Boris Reizis · Columbia University Health Sciences · R01 · FY2014 · AI

Development of a tumor-retentive immunostimulant as adjunct therapy for solid tumor cancers

$395,595
Marcus Laird Forrest · Kinimmune, Inc. · R41 · FY2022 · CA

Sex specific epigenetic regulation of colon cancer metastasis

$395,576
Y. Alan Wang · Indiana University Indianapolis · R01 · FY2023 · CA

University of Maryland Greenebaum Cancer Center Support Grant

$395,573
Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2015 · CA

Angiopoietin-2/Tie2 signaling regulation of liver metastasis in pancreatic neuroendocrine tumors

$395,516
Minah Kim · Columbia University Health Sciences · R37 · FY2024 · CA